DE69633725D1 - Kationische lipide/dns komplexe zum zielen von genen - Google Patents

Kationische lipide/dns komplexe zum zielen von genen

Info

Publication number
DE69633725D1
DE69633725D1 DE69633725T DE69633725T DE69633725D1 DE 69633725 D1 DE69633725 D1 DE 69633725D1 DE 69633725 T DE69633725 T DE 69633725T DE 69633725 T DE69633725 T DE 69633725T DE 69633725 D1 DE69633725 D1 DE 69633725D1
Authority
DE
Germany
Prior art keywords
cationic lipid
complexes
dna complexes
methods
targeting genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633725T
Other languages
English (en)
Other versions
DE69633725T2 (de
Inventor
M Gorman
Molly Mcclarrinon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urigen Pharmaceuticals Inc
Original Assignee
Urigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urigen Pharmaceuticals Inc filed Critical Urigen Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69633725D1 publication Critical patent/DE69633725D1/de
Publication of DE69633725T2 publication Critical patent/DE69633725T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
DE69633725T 1995-06-07 1996-06-07 Kationische lipide/dns komplexe zum zielen von genen Expired - Lifetime DE69633725T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/485,005 US5830878A (en) 1995-06-07 1995-06-07 Cationic lipid: DNA complexes for gene targeting
US485005 1995-06-07
PCT/US1996/009526 WO1996040962A1 (en) 1995-06-07 1996-06-07 Cationic lipid:dna complexes for gene targeting

Publications (2)

Publication Number Publication Date
DE69633725D1 true DE69633725D1 (de) 2004-12-02
DE69633725T2 DE69633725T2 (de) 2005-03-17

Family

ID=23926552

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633725T Expired - Lifetime DE69633725T2 (de) 1995-06-07 1996-06-07 Kationische lipide/dns komplexe zum zielen von genen

Country Status (7)

Country Link
US (2) US5830878A (de)
EP (1) EP0832270B1 (de)
AT (1) ATE280833T1 (de)
AU (1) AU698318B2 (de)
CA (1) CA2223923A1 (de)
DE (1) DE69633725T2 (de)
WO (1) WO1996040962A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052603A2 (en) * 1997-05-23 1998-11-26 Schweiz. Serum- & Impfinstitut Bern An influenza enveloped dna vaccine
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US6093816A (en) * 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
PT941066E (pt) * 1996-08-26 2004-03-31 Transgene Sa Complexos de lipido cationico - acido nucleico
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
WO1998010748A1 (en) * 1996-09-13 1998-03-19 The School Of Pharmacy Liposomes
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US6121457A (en) 1997-11-14 2000-09-19 Megabios Corporation Compositions and methods using novel substituted imidazolium lipids
EP1987845B1 (de) 1997-11-20 2012-03-21 Vical Incorporated Behandlung von Krebs mithilfe Cytokin-exprimierender Polynukleotide und Zusammensetzungen dafür
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP2298728A1 (de) 1998-11-12 2011-03-23 Life Technologies Corporation Transfektionsreagenzien
AUPQ259399A0 (en) 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
KR100373845B1 (ko) * 2000-09-21 2003-02-26 굿젠 주식회사 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
WO2009038779A2 (en) * 2007-09-19 2009-03-26 University Of Tennessee Research Foundation Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
US8044215B2 (en) * 2009-04-29 2011-10-25 Juvaris Biotherapeutics, Inc. Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds
MX345854B (es) 2010-12-22 2017-02-17 Bayer Ip Gmbh Respuesta inmune potenciada en la especie bovina.
JP6772065B2 (ja) 2014-02-28 2020-10-21 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 免疫賦活プラスミド
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
TWI714580B (zh) 2015-05-04 2021-01-01 德商拜耳動物保健有限公司 改良之兩親性咪唑啉化合物的製法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503372A (ja) * 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
US5705655A (en) * 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
EP0698109B1 (de) * 1993-05-10 2002-07-31 The Regents Of The University Of Michigan Gentransfer zu den pankreatischen epithelzellen
EP0730405A4 (de) * 1993-11-24 1997-02-19 Megabios Corp Amphiphile guanidin-derivate
NZ277614A (en) * 1993-11-24 1998-05-27 Megabios Corp Piperazine-containing amphiphiles and their use in liposomes for delivering genetic material intracellularly
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting

Also Published As

Publication number Publication date
AU698318B2 (en) 1998-10-29
US6344446B1 (en) 2002-02-05
AU6160996A (en) 1996-12-30
DE69633725T2 (de) 2005-03-17
EP0832270B1 (de) 2004-10-27
CA2223923A1 (en) 1996-12-19
WO1996040962A1 (en) 1996-12-19
ATE280833T1 (de) 2004-11-15
EP0832270A1 (de) 1998-04-01
US5830878A (en) 1998-11-03

Similar Documents

Publication Publication Date Title
DE69633725D1 (de) Kationische lipide/dns komplexe zum zielen von genen
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
CY1105475T1 (el) Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων
ATE245697T1 (de) Klonierung und expression eines gens, das bryodin 1 aus bryonia dioica kodiert
DE69637718D1 (de) Invertierte Chimäre und Hybrid-Oligonukleotide
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
WO1999033982A3 (en) Human genes and gene expression products i
DE69910216D1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
WO1999038972A3 (en) Human genes and gene expression products ii
WO1999058675A3 (en) Human genes and gene expression products v
TR199902529T2 (xx) Etkinle�tirilmi� protein C form�lasyonlar�.
WO1998002190A3 (en) Cationic amphiphile/dna complexes
ATE337019T1 (de) Geladene lipide und deren verwendung
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
ATE359825T1 (de) J-kette und analoge für konjugate zielgerichtet auf epithelzellen
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
FI963103A (fi) Ei-virusvektori
DE69709407T2 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
WO1999064594A3 (en) Genes and gene expression products that are differentially regulated in prostate cancer
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2022256499A3 (en) Bcma targeting trispecific proteins and methods of use
SE9503117D0 (sv) Novel use of padlock probes
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates

Legal Events

Date Code Title Description
8364 No opposition during term of opposition